Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-06

Study Completion Date

2018-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Oral Lichen Planus (OLP) is an autoimmune, chronic inflammatory mucocutaneous disease characterized by pain and burning sensation. The major types of OLP are the following: reticular, atrophic, erosive-ulcerative, bullous and pigmentous form.Its etiology remains unclear. The presence of auto-cytotoxic T cell clones in the lesions suggests the role of autoimmunity. Numerous treatment options of OLP include topical and systemic agents depending on severity of lesions . Topical corticosteroids abide the mainstay of therapy,and are widely accepted as the primary treatment of choice.Hence this study is designed to evaluate and compare the clinical efficacy of topical Clobetasol 0.05% in orabase and Betamethasone 0.05% in orabase in combination with Clotrimazole 1% in the management of symptomatic Oral Lichen Planus.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus

NCT02443311

Oral Lichen Planus

COMPLETED PHASE4

Mucoadhesive Modified-Release Formulations for the Topical Treatment of Symptomatic Oral Lichen Planus

NCT07100613

Oral Lichen Planus Oral Lichen Planus Related Stress Oral Mucosal Disease +1 more

RECRUITING PHASE2

Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus.

NCT04364555

Oral Lichen Planus

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus

NCT03386643

Oral Lichen Planus

COMPLETED PHASE2

Intra-oral Treatment of OLP With Rivelin®-CLO Patches

NCT03592342

Oral Lichen Planus

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients of either sex, irrespective of age attending the Department of Oral Medicine \& Radiology, Panineeya Mahavidhyalaya Institute of Dental Sciences and Research Centre, Hyderabad who are clinically and histopathologically diagnosed with Oral Lichen Planus shall be included in the study group after obtaining an informed consent from the patients.

Study design: Prospective study.

Sample size:

A total of 30 patients will be randomly divided into 2 groups with 15 patients in each group.

Methodology:

30 patients who are diagnosed with Oral Lichen Planus by clinical and histopathological examination will be randomly assigned into 2 drug groups and burning sensation will be assessed by VAS Scale and also clinical improvement will be assessed at interval of 1 week till 4 weeks.

GROUP A: This group of patients will receive topical Clobetasol 0.05% in orabase and Clotrimazole 1%.

GROUP B: This group of patients will receive topical Betamethasone 0.05% in orabase and Clotrimazole 1%.

Inclusion criteria:

1. Patients with Oral Lichen Planus, who are willing to participate in the study.
2. Patients who are physically healthy and well oriented in time, space and as a person.
3. Patients clinically and histopathologically diagnosed with Oral Lichen Planus.
4. Patients with symptoms i.e. pain and burning sensation due to oral lichen planus.

Exclusion Criteria :

1. Patients with Oral Lichen Planus, who are not willing to participate in the study.
2. Patients with any other mucosal disease or any other skin disease which may be associated with oral lesions.
3. Patients with a known allergy or contraindication to study medications.
4. Patients with systemic diseases, where steroids are contraindicated.
5. Pregnant women.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oral Lichen Planus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Betamethasone dipropionate 0.05%

topical Betamethasone dipropionate 0.05% in orabase with clotrimazole 1% in oral lichen planus two times a day for one month

Group Type EXPERIMENTAL

Betamethasone Dipropionate

Intervention Type DRUG

Clobetasol propionate 0.05%

Topical Clobetasol propionate 0.05% in orabase with clotrimazole 1% in oral lichen planus patients two times a day for a month

Group Type ACTIVE_COMPARATOR

Clobetasol Propionate

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Betamethasone Dipropionate

Intervention Type DRUG

Clobetasol Propionate

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Betamethasone Dipropionate 0.05% gel Clobetasole Propionate 0.05% gel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with Oral Lichen Planus, who are willing to participate in the study.
2. Patients who are physically healthy and well oriented in time, space and as a person.
3. Patients clinically and histopathologically diagnosed with Oral Lichen Planus.
4. Patients with symptoms i.e. pain and burning sensation due to oral lichen planus.

Exclusion Criteria

1. Patients with Oral Lichen Planus, who are not willing to participate in the study.
2. Patients with any other mucosal disease or any other skin disease which may be associated with oral lesions.
3. Patients with a known allergy or contraindication to study medications.
4. Patients with known history of systemic diseases, where steroids are contraindicated.
5. Pregnant women.

Eligible Sex

ALL

Accepts Healthy Volunteers

No